Drug Overview
Pomalyst (pomalidomide; Celgene) is an oral class I thalidomide analog, immunomodulatory drug with antineoplastic activity.
In vitro studies have shown that the drug acts through multiple mechanisms. Evidence suggests that in addition to anti-angiogenic effects, Pomalyst inhibits proliferation and induces apoptosis of hematopoietic tumor cells, and may have antineoplastic effects. Pomalyst also enhanced T cell- and natural killer cell-mediated immunity and inhibited production of pro-inflammatory cytokines by monocytes.
Pomalyst (pomalidomide; Celgene) is an oral class I thalidomide analog, immunomodulatory drug with antineoplastic activity.
In vitro studies have shown that the drug acts through multiple mechanisms. Evidence suggests that in addition to anti-angiogenic effects, Pomalyst inhibits proliferation and induces apoptosis of hematopoietic tumor cells, and may have antineoplastic effects. Pomalyst also enhanced T cell- and natural killer cell-mediated immunity and inhibited production of pro-inflammatory cytokines by monocytes.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Pomalyst : Multiple myeloma
LIST OF FIGURES
Figure 1: Pomalyst for multiple myeloma – SWOT analysis
Figure 2: The authors drug assessment summary of Pomalyst for multiple myeloma
Figure 3: The authors drug assessment summary of Pomalyst for multiple myeloma
Figure 4: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
Table 1: Pomalyst drug profile
Table 2: Pomalyst pivotal trial data in multiple myeloma
Table 3: Pomalyst late-phase trial data in multiple myeloma
Table 4: Pomalyst key ongoing clinical trials in multiple myeloma
Table 5: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Patients treated with Pomalyst across the US, Japan, and five major EU markets, by country, 2017–26
